IL6 and COVID-19: Furthermore, attempts to re-purpose old drugs or trial new agents to treat COVID-19 have been disappointing: hydroxychloroquine showed a lack of effect or even increased harm6, and targeted anti-IL-6 monoclonal antibody (mAb) therapy with sarilumab and tocilizumab has shown mixed results in clinical studies7,8.